可选产品分析
经您允许，我们会使用注重隐私的有限分析来了解哪些研究流程有效。我们不会使用广告跟踪器或会话录制。您可以在偏好设置中更改此选择。请阅读 隐私政策.
The ongoing commercialization and volume scaling of interchangeable biosimilars and complex specialty therapies through Evernorth Specialty & Care Services represents Cigna's premier growth opportunity.
Termination, non-renewal, or severe fee clawbacks on the single pharmacy benefit client contract representing 19% ($52.2B) of FY2025 consolidated revenue.
The Cigna Group ($304.37) presents an asymmetric investment opportunity, trading at an attractive forward multiple against managed care peers. With Fair value assessed at $478.08, Cigna offers 57.1% implied return driven by Evernorth dominant specialty pharmacy volume, resilient commercial self-funded underwriting, and robust annual free cash generation deployed into share buybacks.
The Cigna Group operates from an advantaged structural position across the US healthcare landscape. Through Evernorth Health Services, Cigna administers pharmacy solutions for 118.2 million customers and dispenses critical therapies for complex conditions. Evernorth generated $234.95B in revenue in FY2025, providing immense procurement scale. In parallel, Cigna Healthcare administers medical coverage for 18.4 million members, predominantly through capital-light self-funded arrangements paired with over $8B in stop-loss premium.5
Enterprise earnings are insulated from government-sponsored program volatility. Unlike peers exposed to Medicare Advantage rate cuts, Cigna concentrates on commercial employer plans and fee-based healthcare services. In Q2 2026, total revenues rose 7% to $71.7B and adjusted income from operations increased 6% to $2.1B ($7.78 per share), leading management to raise full-year 2026 adjusted EPS guidance to at least $30.45. Free cash flow reached $8.39B in FY2025, supporting $3.62B in share repurchases.567
At $304.37, Cigna trades at a steep valuation discount relative to peer multiples for CVS, ELV, and UNH. This market pricing overly discounts regulatory scrutiny on pharmacy benefit management, creating a favorable risk-reward skew toward Fair value of $478.08.4
Evernorth generated $234.95B in FY2025 revenue and is accelerating adoption of interchangeable biosimilars, which provides margin expansion in specialty distribution.58
In FY2025, Cigna generated $8.39B in free cash flow on $1.21B capex,, deploying $3.62B to repurchases and guiding to ~$9B in 2026 operating cash flow.3567
Trading at 8.26x forward P/E against CVS at 11.10x, ELV at 14.87x, and UNH at 18.03x, the market heavily discounts regulatory risk, creating substantial multiple expansion upside toward mid fair value of $478.08.
Strong Buy. The Cigna Group trades at an attractive valuation relative to Fair value of $478.08, offering 57.1% upside backed by Evernorth specialty scale, transparent pricing transition, and high cash conversion.
The Cigna Group is a global healthcare services corporation operating through two primary business divisions: Evernorth Health Services and Cigna Healthcare. Evernorth includes Pharmacy Benefit Services and Specialty and Care Services, delivering drug claim adjudication, home delivery, clinical specialty distribution, and care management across 118.2 million pharmacy customers. Evernorth generated $234.95B in FY2025 revenue, representing 85.5% of total enterprise revenue,.
Cigna Healthcare provides commercial insured and self-insured health plans, stop-loss underwriting, and international healthcare solutions serving 18.4 million medical members. Cigna Healthcare generated $47.41B in FY2025 revenue. Cigna focuses heavily on the commercial self-funded employer market, pairing administrative services with integrated specialty pharmacy and stop-loss products.
A combined stress scenario models the compounding impact of an abrupt contract re-pricing on Cigna's largest pharmacy client (representing 19% of external revenues), alongside persistent high-single-digit medical inflation that lifts Cigna Healthcare MCR past 86.5%. Under this joint shock, consolidated EBIT margin compresses from 3.35% in FY2025 to below 2.50%. While Cigna's capital-light structure and strong operating cash flow of ~$9B ensure full debt service coverage on its $31.46B total debt, discretionary share repurchases would decelerate sharply from the $3.62B deployed in FY2025, dampening EPS growth.
In the downside scenario, pricing concessions on major health plan contracts and heightened regulatory scrutiny restrict rebate retention across Evernorth Pharmacy Benefit Services. Simultaneously, persistent healthcare inflation across inpatient and outpatient care keeps Cigna Healthcare MCR elevated near the upper end of historical ranges, slowing cash flow compounding and keeping the valuation multiple depressed.
SEC Form 10-K footnote disclosures confirm that a single pharmacy benefit client accounted for approximately 19% ($52.2B) of total consolidated external revenues in FY2025, up from 16% in FY2024, housed entirely within Evernorth. Total pharmacy customers decreased 4% in 1H 2026 to 118.2M. A contract termination, loss to a competitor, or forced unbundling under FTC scrutiny would decimate Evernorth procurement scale and volume-based manufacturer rebates, driving an estimated 28.5% fair value impairment.8
可能削弱我们投资逻辑的五项变化。
The Cigna Group possesses a narrow economic moat rooted in the immense operational scale of Evernorth Health Services and high switching costs across Cigna Healthcare's commercial employer client base. In FY2025, Evernorth generated $234.95B in revenue, accounting for 85.5% of consolidated revenues,. Operating alongside CVS Caremark and OptumRx in an oligopolistic pharmacy benefit market, Evernorth commands unmatched purchasing power with pharmaceutical manufacturers, capturing volume rebates and driving biosimilar adoption that lowers drug costs for plan sponsors.
Complementing its pharmacy scale, Cigna Healthcare serves 18.4 million medical members primarily through self-funded administrative services arrangements. By pairing ASO fee administration with stop-loss coverage generating over $8B in premiums, Cigna protects employers against catastrophic medical claims while maintaining minimal balance-sheet underwriting risk. Enterprise clients face substantial operational friction and employee disruption when attempting to unbundle these complex care management and pharmacy benefit workflows.
While regulatory inquiries into PBM pricing practices remain active, Cigna is insulating its moat by proactively deploying Evernorth Signature, a transparent cost-plus model with dynamic dispensing fees. Management anticipates Signature will yield margins near 4%, in line with legacy pharmacy products. This transition, combined with an ROIC of 10.16% against a 6.70% WACC, confirms the durability of Cigna's economic moat.
In FY2025, Cigna generated $9.20B in GAAP operating income on $274.90B in revenue,. Applying the 19.19% effective tax rate yields net operating profit after tax (NOPAT) of $7.43B. Evaluated against year-end invested capital of $73.18B, Cigna achieved an ROIC of 10.16%, comfortably exceeding its computed WACC of 6.70% by 346 basis points. This positive economic spread demonstrates that Cigna's scale and capital efficiency compound enterprise value above its cost of capital.267
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
The highlighted cell is Fair value when every assumption sits at its base level ($478.08). Each row and column shows what Fair value becomes when one assumption moves.
A free-cash-flow drop test is not available in this run; use the discount-rate and terminal-growth grid as the primary valuation pressure test.
Under the bull scenario, biosimilar adoption accelerates beyond management expectations, expanding specialty pharmacy margins. Commercial employer enrollment grows in Middle and Select markets, while transparent Evernorth Signature contracts scale rapidly with early adopters. Enterprise earnings compound at the upper end of management's 10-14% long-term target, driving valuation multiple expansion toward the high end of our fair value range ($825.00).5
An earnings beat driven by biosimilar volume adoption and commercial stop-loss underwriting margin expansion validates the core compounding thesis and supports management long-term double-digit EPS growth algorithm.
Meeting reaffirmed guidance confirms steady EPS compounding, supported by consistent share count retirement and resilient commercial employer underwriting.
A guidance reduction or margin deterioration in pharmacy benefit services indicates intensified pricing pressure, unrecovered medical inflation, or market share losses.
Cigna exhibits robust earnings quality underpinned by strong cash conversion. In FY2025, operating cash flow reached $9.60B and free cash flow stood at $8.39B, significantly exceeding GAAP net income of $5.96B (141% FCF-to-net-income conversion),,. The primary adjustments between GAAP net income of $6.29 per share and adjusted operating income of $7.78 per share in Q2 2026 consist of predictable non-cash intangible amortization ($1.12 per share) and strategic optimization costs ($0.20 per share). Operating accruals remain clean with minimal non-operating noise.67
Following the Q2 2026 earnings release and management's guidance increase to at least $30.45 per share, consensus earnings expectations have revised upward. Consensus FY2026 EPS rose from $30.41 pre-event to $30.51 currently, with 24 analysts contributing. FY2027 EPS consensus advanced from $33.48 to $33.49. Revenue estimates similarly strengthened, rising to $287.45B for FY2026 and $299.16B for FY2027,.15
High-margin specialty generics and biosimilars expand Evernorth Specialty and Care pre-tax earnings, offsetting retail pharmacy margin normalization.
Cigna's cash flow profile is exceptionally strong, characterized by low capital reinvestment needs and high cash conversion. In FY2025, the company delivered $9.60B in operating cash flow and $8.39B in free cash flow on $5.96B of GAAP net income,,. Free cash flow conversion stood at 141% of net income and 87.4% of operating cash flow. For FY2026, management reaffirmed operating cash flow expectations of approximately $9B, alongside an Investor Day cumulative operating cash flow target of ~$50B through 2030. Working capital swings remain predictable due to commercial fee collection schedules and stop-loss claims settlement cycles.567
Cigna's ROIC demonstrates steady, durable capital efficiency. With invested capital at $73.18B and FY2025 operating income at $9.20B, after-tax operating profit of $7.43B produces an ROIC of 10.16%. The business model relies heavily on working capital velocity and customer contract scale rather than heavy property, plant, and equipment additions, ensuring returns on capital remain durable as biosimilar volumes scale.
Cigna's ROIC of 10.16% comfortably outpaces its computed WACC of 6.7034% by 346 basis points. This positive economic spread reflects Cigna's procurement power and disciplined commercial pricing, confirming that enterprise reinvestment continues to generate economic shareholder value.
Cigna generated $8.39B in free cash flow on $1.21B in FY2025 ( of 0.44%),,.
| 营业收入 | US$71,668,000,000 |
|---|---|
| 营业成本 | US$56,703,000,000 |
| 毛利 | US$14,965,000,000 |
| 营业费用 | US$12,289,000,000 |
| 营业利润 | US$2,676,000,000 |
| 营业外项目及税项 | -US$1,016,000,000 |
| 净利润 | US$1,660,000,000 |
| 总资产 | US$157,919,000,000 |
|---|---|
| 现金 | US$7,676,000,000 |
| 流动资产 | US$47,814,000,000 |
| 总负债 | US$116,045,000,000 |
| 流动负债 | US$56,342,000,000 |
| 股东权益 | US$41,874,000,000 |
| 净利润 | US$5,957,000,000 |
|---|---|
| 经营现金流入 | US$9,601,000,000 |
| 折旧与摊销 | US$2,775,000,000 |
| 其他经营调整项 | US$869,000,000 |
| 经营现金流 | US$9,601,000,000 |
| 可用现金 | US$18,564,000,000 |
| 期初现金 | US$8,931,000,000 |
| 汇率影响 | US$32,000,000 |
| 投资现金流出 | US$4,407,000,000 |
| 资本支出 | US$1,212,000,000 |
| 其他投资活动 | US$3,195,000,000 |
| 融资现金流出 | US$6,421,000,000 |
| 股份回购 | US$3,621,000,000 |
| 已付股息 | US$1,611,000,000 |
| 净债务偿还 | US$667,000,000 |
| 其他融资活动 | US$522,000,000 |
| 期末现金 | US$7,736,000,000 |
| 投资现金流 | -US$4,407,000,000 |
| 融资现金流 | -US$6,421,000,000 |
| 按业务类别划分的收入 | 营业收入 | 占比 | 同比 |
|---|---|---|---|
| Cost of | 567亿 | 79.1% | — |
| Other | 149.7亿 | 20.9% | — |
2026-10-22分析所采用的时点财务数据。
| 期间 | 营业收入 | EBITDA | 净利润 | 经营现金流 | 自由现金流 | 资本支出 | 折旧与摊销 | 股份支付 | 股份回购 | 已付股息 | 净债务发行 | 投资现金流 | 融资现金流 | 期初现金 | 期末现金 | 现金与投资 | 总债务 | 营业利润率 | ROIC | WACC | ROIC−WACC利差 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | US$398.4亿 | US$38.6亿 | US$18.7亿 | US$40.3亿 | US$35.7亿 | US$4.6亿 | US$6.1亿 | US$1.3亿 | US$1.4亿 | US$0 | — | -US$25.7亿 | -US$2.3亿 | — | US$31.9亿 | US$38.8亿 | US$50.3亿 | 7.8% | — | — | — |
| 2017-12-31 | US$418.1亿 | US$46.9亿 | US$22.4亿 | US$40.9亿 | US$36.2亿 | US$4.7亿 | US$5.7亿 | US$1.8亿 | US$27.3亿 | US$16.6亿 | — | -US$17亿 | -US$26.5亿 | US$31.9亿 | US$29.7亿 | US$51.1亿 | US$54.4亿 | 9.4% | — | — | — |
| 2018-12-31 | US$486.5亿 | US$55.6亿 | US$26.4亿 | US$37.7亿 | US$32.4亿 | US$5.3亿 | US$7亿 | US$1.8亿 | US$3.4亿 | US$243.4亿 | — | -US$263.8亿 | US$235.2亿 | US$29.7亿 | US$38.6亿 | US$59亿 | US$424.8亿 | 8.6% | — | 4.4% | — |
| 2019-12-31 | US$1535.7亿 | US$124.7亿 | US$51亿 | US$94.9亿 | US$84.4亿 | US$10.5亿 | US$36.5亿 | US$3亿 | US$19.9亿 | US$1500万 | — | -US$7.3亿 | -US$71.9亿 | US$38.6亿 | US$46.7亿 | US$55.6亿 | US$380.4亿 | 5.3% | — | 4.0% | — |
| 2020-12-31 | US$1604亿 | US$113.7亿 | US$84.6亿 | US$103.5亿 | US$92.6亿 | US$10.9亿 | US$28亿 | US$2.9亿 | US$40.4亿 | US$3.5亿 | — | US$29.8亿 | -US$85.3亿 | US$46.7亿 | US$102.5亿 | US$115.1亿 | US$335.6亿 | 5.1% | — | 3.4% | — |
| 2021-12-31 | US$1740.7亿 | US$110.9亿 | US$53.7亿 | US$71.9亿 | US$60.4亿 | US$11.5亿 | US$29.2亿 | US$2.7亿 | US$77.4亿 | US$3.6亿 | — | -US$36.1亿 | -US$82.1亿 | US$102.5亿 | US$51.2亿 | US$60亿 | US$342.7亿 | 4.6% | — | 4.0% | — |
| 2022-12-31 | US$1805.2亿 | US$115.2亿 | US$67亿 | US$86.6亿 | US$73.6亿 | US$13亿 | US$29.4亿 | US$2.6亿 | US$76.1亿 | US$3.7亿 | -US$25.6亿 | US$31亿 | -US$112.4亿 | US$55.5亿 | US$59.8亿 | US$68.3亿 | US$315.5亿 | 4.7% | — | 6.1% | — |
| 2023-12-31 | US$1952.7亿 | US$120.7亿 | US$51.6亿 | US$118.1亿 | US$102.4亿 | US$15.7亿 | US$30.4亿 | US$2.9亿 | US$22.8亿 | US$14.5亿 | -US$2.8亿 | -US$51.7亿 | -US$42.9亿 | US$59.8亿 | US$78.7亿 | US$87.5亿 | US$309.3亿 | 4.4% | — | 6.0% | — |
| 2024-12-31 | US$2471.2亿 | US$124.7亿 | US$34.3亿 | US$103.6亿 | US$89.6亿 | US$14.1亿 | US$27.8亿 | US$3.1亿 | US$70.3亿 | US$15.7亿 | US$10.6亿 | -US$21亿 | -US$76.5亿 | US$83.4亿 | US$75.9亿 | US$82.2亿 | US$319.7亿 | 3.8% | — | 6.2% | — |
| 2025-12-31 | US$2749亿 | US$117.5亿 | US$59.6亿 | US$96亿 | US$83.9亿 | US$12.1亿 | US$27.8亿 | — | US$36.2亿 | US$16.1亿 | -US$6.7亿 | -US$44.1亿 | -US$64.2亿 | US$89.3亿 | US$77.4亿 | US$87.3亿 | US$314.6亿 | 3.3% | — | 5.3% | — |
The Cigna Group (CI) trades at 8.3x forward earnings against a peer median of 16.4x. Its EV/EBITDA of 8.3x compares with a peer median of 11.4x. The comparison uses 4 peers: Elevance Health Inc., CVS Health Corporation, Humana Inc. and UnitedHealth Group Incorporated, as of 2026-10-21.
Industry benchmark data confirms low capital intensity across healthcare services, with an industry capex-to-revenue ratio of 0.90% (0.009) and capex-to-depreciation ratio of 0.81. Cigna's actual FY2025 capex was $1.21B on $274.90B revenue, representing a capex-to-revenue ratio of just 0.44%,.37
In a cyclical upswing, rapid penetration of lower-cost biosimilars expands specialty pharmacy operating margins, while commercial premium rate increases outpace outpatient utilization trends. Employer health plan sponsors expand self-funded coverage, lifting stop-loss premium volumes above $8B and accelerating enterprise adjusted EPS compounding toward the upper end of management's 10-14% long-term target.
In a cyclical downturn, prolonged high-single-digit medical inflation outpaces commercial underwriting premium increases, driving medical care ratios above 86% and eroding risk margins. Concurrently, aggressive legislative bans on PBM spread pricing or employer client losses under antitrust unbundling scrutiny would compress pharmacy services margins and reduce fee-based earnings.
The Cigna Group is strategically positioned where healthcare costs concentrate: complex specialty therapies and commercial employer risk management. Unlike competitors heavily exposed to Medicare Advantage rate adjustments, Cigna derives over 85% of revenue from Evernorth Health Services, which benefits from volume-driven specialty pharmaceutical consumption. In commercial medical underwriting, Cigna's emphasis on self-funded ASO plans paired with stop-loss reinsurance minimizes underwriting balance-sheet volatility.8
High conviction is supported by Cigna's narrow economic moat in specialty pharmacy, premier cash flow generation ($8.39B FCF in FY2025), an 8.26x forward P/E multiple, and an 8.5% EPS compounding trajectory.36
Risk is managed through disciplined portfolio position sizing (5-7%), continuous monitoring of quarterly medical care ratios against the 83.7%-84.7% corridor, and tracking Evernorth Signature customer adoption ahead of 2027-2028 commercial scaling. The planned exit from the ACA Individual and Family Plans exchange business by January 1, 2027 removes underwriting volatility from the risk book.
At 8.26x forward earnings, Cigna trades at a steep discount to CVS (11.10x), ELV (14.87x), and UNH (18.03x). The 57.07% implied upside to mid fair value ($478.08) provides significant upside potential.34
Evernorth specialty pharmacy volume and expanding biosimilar distribution underpin an 8.5% EPS compounding trajectory and long-term 10-14% EPS growth targets, powered by ~$9B in annual operating cash flow.5
Investors focused strictly on PBM legislative headline risk should hold existing allocations while monitoring FTC developments, noting that current depressed multiples already price in significant regulatory friction.
We assign a Strong Buy rating to The Cigna Group with Fair value of $478.08, representing 57.1% implied upside from $304.37,.3
Cigna combines dominant specialty pharmacy procurement scale, high free cash flow conversion ($8.39B in FY2025), and aggressive share repurchases, trading at an unwarranted discount of 8.26x forward earnings relative to peers.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Consolidated operating margin contracted steadily from 5.26% in FY2019 to 3.35% in FY2025,. In Q2 2026, Pharmacy Benefit Services pre-tax operating income fell 27% due to client pricing concessions and contract renewals. Bipartisan congressional legislation or FTC enforcement mandating 100% rebate pass-through and eliminating spread pricing would compress pharmacy services margins, pulling consolidated EBIT margin below 2.50% and driving an estimated 35.0% fair value impairment.7
Cigna Healthcare MCR increased to 84.5% in Q2 2026 from 83.2% in Q2 2025, approaching the upper boundary of full-year guidance of 83.7%-84.7%. Healthcare cost trends remain persistently elevated in high single digits across inpatient and outpatient care. If commercial underwriting pricing fails to outpace medical inflation and stop-loss claims surge, an MCR exceeding 86.5% would severely erode commercial earnings, driving an estimated 22.0% fair value impairment.5
Cigna trades at 8.26x forward P/E, discounted relative to peers CVS (11.10x), ELV (14.87x), and UNH (18.03x). If formal FTC antitrust litigation or legislative caps on PBM administrative fees materialize, multiple compression of 20% to below 7.0x would wipe out capital return gains, reducing fair value by an estimated 25.0%.34
Legislative bans on rebate retention or mandatory 100% pass-through pricing eroding Pharmacy Benefit Services profitability beyond cost-plus transition offsets.
当前：3.35% for FY2025,
触发警报：Consolidated EBIT margin falling below 2.50%
Commercial premium rate adjustments failing to match persistent high-single-digit medical inflation across inpatient and outpatient settings.
当前：84.5% in Q2 2026 against full-year guidance of 83.7%-84.7%
触发警报：MCR exceeding 86.5%
Market valuation multiple de-rating from regulatory litigation or legislative fee restrictions, overwhelming earnings compounding from share repurchases.
当前：8.26x forward P/E as of 2026-10-22
触发警报：Forward multiple compressing below 7.0x
Accelerating client attrition and membership losses across health plan clients reducing purchasing leverage and rebate negotiations.
当前：118.2M at June 30, 2026
触发警报：Total pharmacy customers falling below 110.0M
| Customer Concentration in Evernorth Pharmacy Benefit Services | medium | 18-36 months | Expanding multi-client specialty distribution, accelerating biosimilar and specialty generic penetration, and broadening middle-market commercial accounts,.5 |
| Persistent Inpatient and Outpatient Medical Utilization Inflation | medium | 6-18 months | Disciplined commercial renewal pricing to match forward medical cost trends, active stop-loss risk management, and the strategic exit from the volatile Individual and Family Plans ACA exchange business by January 1, 2027.5 |
Under the moderate discount rate, US$125 comes from forecast-period earnings and US$647 from the long-term value, totaling US$772.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Solve for the growth rate that makes the model value equal the report-date share price.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
The base case represents the modal expected trajectory, delivering an 8.5% EPS compounding path. Consensus FY2026 EPS of $30.51 and FY2027 EPS of $33.48 are met as Evernorth specialty volume offsets retail pharmacy pricing concessions. Re-rating to mid fair value of $478.08 reflects steady execution and capital return.1
Measures whether commercial premium rate increases sufficiently outpace persistent high-single-digit medical inflation across inpatient and outpatient care.
Validates Cigna's ability to migrate commercial pharmacy relationships toward transparent fee-based models without sacrificing segment operating income.
Consistent share repurchases reduce diluted share count annually, serving as a primary pillar of enterprise EPS compounding.
| $312.29B |
| $323.22B |
| $332.92B |
| Operating income | $9.67B | $10.36B | $11.09B | $11.80B | $12.32B |
| NOPAT | $7.73B | $8.28B | $8.86B | $9.43B | $9.85B |
| Residual cash after reinvestment policy | $3.79B | $4.06B | $4.34B | $4.62B | $4.83B |
| Revenue growth | 5.0% | 4.1% | 4.0% | 3.5% | 3.0% |
| Operating margin | 3.4% | 3.5% | 3.6% | 3.7% | 3.7% |
| Tax rate | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% |
| Reinvestment rate | 51.0% | 51.0% | 51.0% | 51.0% | 51.0% |
| Terminal growth | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
Evernorth produced $234.95B of Cigna's $274.90B FY2025 revenue (85.5%), while Cigna Healthcare contributed $47.41B,,.
Volume-driven specialty pharmacy cash flows shield enterprise operating income from medical loss ratio volatility that severely impacts pure-play health insurers.
Total debt of $31.46B represents a 28.39% debt weight against an $80.43B market capitalization,,.
With a pre-tax cost of debt of 5.80% and $9B+ in annual operating cash flow, debt service requirements are easily met, leaving ample balance sheet capacity.
| 利润率 |
|---|
| CI | The Cigna Group | $80.4B | 8.3x | 0.3x | 8.3x | 16.8% | — |
| ELV | Elevance Health Inc. | $95.5B | 14.9x | 0.5x | 10.7x | 11.1% | 4.6% |
| CVS | CVS Health Corporation | $121.2B | 11.1x | 0.3x | 11.0x | 6.2% | 3.9% |
| HUM | Humana Inc. | $51.3B | 25.0x | 0.4x | 11.8x | 6.9% | 3.5% |
| UNH | UnitedHealth Group Incorporated | $376.3B | 18.0x | 0.8x | 14.7x | 15.8% | 5.8% |
| Commercial Employer Shift Toward Self-Funded Health Plans | positive | Commercial employers continue shifting from guaranteed-cost risk policies to self-funded (ASO) structures to manage healthcare expenditure, driving demand for Cigna's integrated medical administration and stop-loss risk transfer. |
| Persistent Healthcare Utilization and Unit Cost Inflation | negative | Elevated medical cost inflation in high single digits across inpatient and outpatient care puts upward pressure on commercial medical care ratios when annual premium pricing adjustments lag utilization spikes. |
| Single PBM Client Revenue Concentration | Loss of major client contract or external revenue share dropping below 10% | Re-underwrite intrinsic fair value for volume dis-economies and lower conviction to moderate. |
